Daily Endocrinology Research Analysis
Three standout endocrinology papers span clinical translation, device innovation, and mechanistic biology: a randomized phase 4 trial (SURPASS-SWITCH) finds switching from dulaglutide to tirzepatide yields greater HbA1c reduction than dose escalation; a biorhythm-mimicking growth hormone microneedle patch enhances bone growth versus daily injections in rodents; and new mechanistic work reveals metabolic and paracrine heterogeneity among pancreatic alpha-cells governing glucagon secretion.
Summary
Three standout endocrinology papers span clinical translation, device innovation, and mechanistic biology: a randomized phase 4 trial (SURPASS-SWITCH) finds switching from dulaglutide to tirzepatide yields greater HbA1c reduction than dose escalation; a biorhythm-mimicking growth hormone microneedle patch enhances bone growth versus daily injections in rodents; and new mechanistic work reveals metabolic and paracrine heterogeneity among pancreatic alpha-cells governing glucagon secretion.
Research Themes
- Optimizing incretin-based therapy sequencing in type 2 diabetes
- Chronopharmacology-inspired hormone delivery via microneedle technology
- Islet alpha-cell metabolic/paracrine heterogeneity shaping glucagon secretion
Selected Articles
1. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
In adults with type 2 diabetes inadequately controlled on lower-dose dulaglutide, switching to tirzepatide achieved greater HbA1c reductions than escalating dulaglutide dose in a multicenter, open-label phase 4 RCT. Safety findings were consistent with known profiles, supporting a treatment sequencing strategy favoring tirzepatide switch.
Impact: Head-to-head randomized evidence directly informs a common clinical decision: up-titrate GLP-1 RA versus switch to a dual GIP/GLP-1 RA. Results favor switching, with implications for guidelines and formularies.
Clinical Implications: For patients with suboptimal control on dulaglutide, clinicians should consider switching to tirzepatide rather than dose escalation to achieve greater glycemic improvement and likely additional weight loss, while monitoring gastrointestinal adverse events.
Key Findings
- Switching from dulaglutide to tirzepatide produced greater HbA1c reduction than escalating dulaglutide dose.
- Multicenter, randomized, open-label, phase 4 design across 38 sites in 5 countries with 282 randomized participants.
- Safety profile was consistent with known class effects; open-label design noted as a limitation.
Methodological Strengths
- Randomized, active-controlled, multicenter phase 4 trial
- Pre-specified primary endpoint (HbA1c change) with registered protocol (NCT05564039)
Limitations
- Open-label design may introduce performance and detection bias
- Abstract does not report detailed effect sizes or duration
Future Directions: Report full efficacy and safety data including HbA1c and weight effect sizes, durability, patient-reported outcomes, and cost-effectiveness to inform treatment algorithms.
BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for the treatment of adults with type 2 diabetes or obesity, showed clinically meaningful reductions in hemoglobin A OBJECTIVE: To compare efficacy and safety of escalation of dulaglutide dose versus switching to tirzepatide in inadequately controlled type 2 diabetes. DESIGN: Multicenter, randomized, open-label, phase 4 trial (SURPASS-SWITCH [A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching from Weekly Dulaglutide to Weekly Tirzepatide in Adults with Type 2 Diabetes], ClinicalTrials.gov: NCT05564039). SETTING: 38 sites across 5 countries. PARTICIPANTS: Adults with HbA INTERVENTION: Escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD) or switching to tirzepatide. MEASUREMENTS: The primary end point was change from baseline in HbA RESULTS: A total of 282 adults were randomly assigned to tirzepatide ( LIMITATION: Open-label design. CONCLUSION: In SURPASS-SWITCH, switching treatment to tirzepatide provided additional HbA
2. Biorhythm-mimicking growth hormone patch.
A multistage-release microneedle patch that mimics nocturnal growth hormone pulsatility outperformed daily subcutaneous injections in rodent models, increasing bone length by ~10 mm (healthy rats) and ~5 mm (GH knockout mice), and improving bone quality. The chronopharmacology-aligned profile boosted IGF-1 and GH bioavailability.
Impact: Introduces a programmable, physiology-mimicking hormone delivery platform with superior preclinical efficacy, potentially transforming pediatric and adult GH replacement by aligning with natural secretion rhythms.
Clinical Implications: If translated to humans, nocturnal, pulsatile-mimicking GH delivery could enhance efficacy, adherence, and bone outcomes versus daily injections; clinical studies must assess pharmacokinetics, safety, immunogenicity, and real-world usability.
Key Findings
- Engineered a microneedle patch with burst and delayed-release modules to mimic nocturnal GH pulsatility.
- Enhanced longitudinal bone growth (~10 mm in healthy rats; ~5 mm in GH knockout mice) and improved bone quality versus daily subcutaneous GH.
- Increased IGF-1 secretion and GH bioavailability with biorhythm-mimicking release.
Methodological Strengths
- Innovative programmable drug-release design with clear mechanistic rationale (chronopharmacology)
- Efficacy demonstrated across two in vivo models (healthy rats and GH knockout mice)
Limitations
- Preclinical animal study; no human pharmacokinetic or safety data
- Manufacturing scalability and long-term device tolerability remain untested
Future Directions: Conduct first-in-human studies to assess pharmacokinetics, safety, and efficacy versus standard GH injections, and evaluate adherence, patient experience, and cost-effectiveness.
Timing dosing throughout the day impacts the therapeutic efficacy and side effects of medications. Thus, optimizing release profiles to synchronize drug concentrations with natural rhythms is critical for optimal therapeutic benefits. However, existing delivery systems are still inefficient in delivering drugs in a biorhythm-mimicking fashion. Here we describe a biorhythm-inspired growth hormone transdermal microneedle patch with multistage drug release that mimics the natural rhythm of human growth hormone secretion at night. Programmed drug release is achieved by combining a 'burst-release' module with several 'delayed-release' modules. Compared with the subcutaneous daily injections currently used in clinics, the patch exhibits enhanced efficacy in terms of longitudinal bone growth and bone quality, leading to bone length increases of ~10 mm and ~5 mm in healthy rats and growth hormone gene knockout mice, respectively. Our findings reveal that the biorhythm-mimicking release pattern significantly enhances growth hormone bioavailability and effectively regulates the growth-related biological process, thus boosting the secretion of insulin-like growth factor-1 and ultimately promoting bone growth.
3. Metabolic and Paracrine Heterogeneity of Pancreatic Glucagon-Secreting α-Cells.
Using optogenetics, electrophysiology, Ca2+ imaging, and secretion assays, the study shows that up to ~50% of α-cells are electrically silent at low glucose but can be activated by KATP blockade, amino acids, or somatostatin receptor antagonism. δ-cell optogenetic manipulation bidirectionally modulates neighboring α-cell activity, and amino acid stimulatory effects inversely track basal glucagon release, revealing metabolic and paracrine heterogeneity shaping glucagon secretion.
Impact: Provides mechanistic insight into α-cell heterogeneity, identifying distinct electrically silent versus active subpopulations and δ-cell proximity as key determinants of glucagon control—opening avenues for targeted modulation of hyperglucagonaemia in diabetes.
Clinical Implications: Therapeutic strategies that modulate KATP channel activity in α-cells or somatostatin signaling at the α–δ microcircuit may fine-tune glucagon in diabetes; heterogeneity suggests precision approaches rather than uniform suppression.
Key Findings
- Approximately 50% of α-cells are electrically silent at 1 mmol/L glucose but can be activated by KATP blockade, amino acids, or somatostatin receptor antagonists.
- Optogenetic activation/inhibition of δ-cells bidirectionally regulates electrical activity in adjacent, but not distal, α-cells.
- Amino acid stimulatory effects on glucagon secretion inversely correlate with basal glucagon release; α-cell excitability reflects a mosaic of KATP and somatostatin-sensitive K+ channels and δ-cell proximity.
Methodological Strengths
- Multimodal approach combining optogenetics, patch-clamp electrophysiology, Ca2+ imaging, and secretion assays
- Cell-type specific manipulation (δ-cells) with spatially resolved effects on nearby α-cells
Limitations
- Predominantly ex vivo and rodent islet experiments; human translational validation is needed
- Complex islet microcircuitry may introduce species-specific differences
Future Directions: Validate α-cell subpopulation behavior and δ–α microcircuit effects in human islets and in vivo; explore pharmacologic modulators of KATP and somatostatin pathways to normalize glucagon in diabetes.
UNLABELLED: By stimulating hepatic glucose production, glucagon (released by islet α-cells) restores normal blood glucose levels when they fall below the normal range. We used optogenetics in conjunction with electrophysiology, cytoplasmic free Ca2+ concentration imaging, and hormone release measurements to explore the intrinsic and paracrine regulation of glucagon secretion. Many α-cells were spontaneously active at 1 mmol/L glucose. However, up to ∼50% of the α-cells were electrically silent. KATP channel blockade, amino acids, and somatostatin receptor antagonism restored electrical activity in such α-cells. Termination of optoactivation resulted in KATP channel-dependent (tolbutamide sensitive) membrane repolarization in active α-cells but long-lasting membrane depolarization and action potential firing in silent α-cells. The latter effect was associated with an increased cytoplasmic ATP:ADP ratio. Optoactivation or optoinhibition of somatostatin-releasing δ-cells inhibits and stimulates electrical activity in adjacent (but not distal) α-cells. There is an inverse relationship between basal glucagon secretion (a measure of the fraction active α-cells) and the relative stimulatory effects of amino acids. We conclude that islet α-cells are functionally heterogenous and that their electrical excitability and glucagon release are determined by K+ channel activity due to variable mosaic of KATP and somatostatin-sensitive K+ channels reflecting metabolic state and proximity to δ-cells, respectively. ARTICLE HIGHLIGHTS: A subpopulation of α-cells lack spontaneous electrical activity. KATP channel blockers, somatostatin receptor antagonists, or amino acids activate silent α-cells. Stimulatory effects of amino acids are inversely related to basal glucagon secretion. Metabolic and paracrine heterogeneity determines glucagon secretion.